These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 7749064

  • 1. Multifunctional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors.
    Hale KK, Smith CG, Baker SL, Vanderslice RW, Squires CH, Gleason TM, Tucker KK, Kohno T, Russell DA.
    Cytokine; 1995 Jan; 7(1):26-38. PubMed ID: 7749064
    [Abstract] [Full Text] [Related]

  • 2. IL-4 and TNF-alpha-mediated proliferation of the human megakaryocytic line M-O7E is regulated by induced autocrine production of GM-CSF.
    Wadhwa M, Dilger P, Meager A, Walker B, Gaines-Das R, Thorpe R.
    Cytokine; 1996 Dec; 8(12):900-9. PubMed ID: 9050748
    [Abstract] [Full Text] [Related]

  • 3. Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.
    Corcoran AE, Scallon BJ, Trinh H, Chernajovsky Y, Ghrayeb J, Feldmann M.
    Eur Cytokine Netw; 1998 Sep; 9(3):255-62. PubMed ID: 9831174
    [Abstract] [Full Text] [Related]

  • 4. The role of type I and type II tumor necrosis factor (TNF) receptors in the ability of TNF-alpha to transduce a proliferative signal in the human megakaryoblastic leukemic cell line Mo7e.
    Liu RY, Fan C, Mitchell S, Chen Q, Wu J, Zuckerman KS.
    Cancer Res; 1998 May 15; 58(10):2217-23. PubMed ID: 9605769
    [Abstract] [Full Text] [Related]

  • 5. TNF-alpha blockade by a dimeric TNF type I receptor molecule selectively inhibits adaptive immune responses.
    Colagiovanni DB, Suniga MA, Frazier JL, Edwards CK, Fleshner M, McCay JA, White KL, Shopp GM.
    Immunopharmacol Immunotoxicol; 2000 Nov 15; 22(4):627-51. PubMed ID: 11105778
    [Abstract] [Full Text] [Related]

  • 6. A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo.
    Yan Z, Zhao N, Wang Z, Li B, Bao C, Shi J, Han W, Zhang Y.
    Cytotherapy; 2006 Nov 15; 8(4):415-23. PubMed ID: 16923618
    [Abstract] [Full Text] [Related]

  • 7. Tumor necrosis factor (TNF)-soluble high-affinity receptor complex as a TNF antagonist.
    McKenna SD, Feger G, Kelton C, Yang M, Ardissone V, Cirillo R, Vitte PA, Jiang X, Campbell RK.
    J Pharmacol Exp Ther; 2007 Aug 15; 322(2):822-8. PubMed ID: 17495128
    [Abstract] [Full Text] [Related]

  • 8. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis.
    Glossop JR, Dawes PT, Nixon NB, Mattey DL.
    Arthritis Res Ther; 2005 Aug 15; 7(6):R1227-34. PubMed ID: 16277675
    [Abstract] [Full Text] [Related]

  • 9. The functional role of 55- and 75-kDa tumour necrosis factor receptors in human polymorphonuclear cells in vitro.
    Abe Y, Osuka Y, Nakata T, Kashu Y, Kimura S.
    Cytokine; 1995 Jan 15; 7(1):39-49. PubMed ID: 7749065
    [Abstract] [Full Text] [Related]

  • 10. The glucocorticoid antagonist RU38486 mimics interleukin-1 in its sensitization to the lethal and interleukin-6-inducing properties of tumor necrosis factor.
    Brouckaert P, Everaerdt B, Fiers W.
    Eur J Immunol; 1992 Apr 15; 22(4):981-6. PubMed ID: 1532365
    [Abstract] [Full Text] [Related]

  • 11. Tumor necrosis factor-alpha modulates the expression of its p60 receptor and several cytokines in rat tracheal epithelial cells.
    Bader T, Nettesheim P.
    J Immunol; 1996 Oct 01; 157(7):3089-96. PubMed ID: 8816419
    [Abstract] [Full Text] [Related]

  • 12. Increased synovial fluid levels of interleukin-12, sCD25 and sTNF-RII/sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies.
    Ribbens C, André B, Kaye O, Kaiser MJ, Bonnet V, de Groote D, Franchimont N, Malaise MG.
    Eur Cytokine Netw; 2000 Dec 01; 11(4):669-76. PubMed ID: 11125312
    [Abstract] [Full Text] [Related]

  • 13. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
    Crippa L, Gasparri A, Sacchi A, Ferrero E, Curnis F, Corti A.
    Cancer Res; 2008 Feb 15; 68(4):1154-61. PubMed ID: 18281491
    [Abstract] [Full Text] [Related]

  • 14. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis.
    Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I, Iwaoka Y, Saniabadi A.
    Am J Gastroenterol; 2004 Aug 15; 99(8):1532-8. PubMed ID: 15307873
    [Abstract] [Full Text] [Related]

  • 15. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia.
    Gelin J, Moldawer LL, Lönnroth C, Sherry B, Chizzonite R, Lundholm K.
    Cancer Res; 1991 Jan 01; 51(1):415-21. PubMed ID: 1703040
    [Abstract] [Full Text] [Related]

  • 16. TNF receptor p55 plays a major role in centrally mediated increases of serum IL-6 and corticosterone after intracerebroventricular injection of TNF.
    Benigni F, Faggioni R, Sironi M, Fantuzzi G, Vandenabeele P, Takahashi N, Sacco S, Fiers W, Buurman WA, Ghezzi P.
    J Immunol; 1996 Dec 15; 157(12):5563-8. PubMed ID: 8955207
    [Abstract] [Full Text] [Related]

  • 17. Selective up-regulation of tumor necrosis factor receptor I in tumor-bearing rats with cancer-related cachexia.
    Catalano MG, Fortunati N, Arena K, Costelli P, Aragno M, Danni O, Boccuzzi G.
    Int J Oncol; 2003 Aug 15; 23(2):429-36. PubMed ID: 12851692
    [Abstract] [Full Text] [Related]

  • 18. Tumor necrosis factor alpha-induced activation of c-jun N-terminal kinase is mediated by TRAF2.
    Reinhard C, Shamoon B, Shyamala V, Williams LT.
    EMBO J; 1997 Mar 03; 16(5):1080-92. PubMed ID: 9118946
    [Abstract] [Full Text] [Related]

  • 19. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.
    Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB.
    J Immunol; 1993 Aug 01; 151(3):1548-61. PubMed ID: 8393046
    [Abstract] [Full Text] [Related]

  • 20. A long-acting tumor necrosis factor alpha-binding protein demonstrates activity in both in vitro and in vivo models of endometriosis.
    Altan ZM, Denis D, Kagan D, Grund EM, Palmer SS, Nataraja SG.
    J Pharmacol Exp Ther; 2010 Aug 01; 334(2):460-6. PubMed ID: 20435921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.